GlassScriptPhysician profile
Sarah E Drennan
NPI 1194952135
$4,130.90
in general payments reported to CMS, 2019-2025
25 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $86.70 · 2021: $246 · 2022: $202 · 2023: $313 · 2024: $2,799 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,594 · Travel and Lodging: $1,084 · Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,594.00 |
| Travel and Lodging | $1,083.59 |
| Food and Beverage | $817.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,673.43 | 2024 | |
| Astellas Pharma US INC | $246.68 | 2023-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $125.09 | 2020-2023 | Orilissa, Lo Loestrin Fe |
| Lsi Solutions INC | $124.53 | 2021 | |
| Novo Nordisk INC | $121.82 | 2025 | Wegovy |
| Pfizer INC. | $120.35 | 2021-2023 | |
| Hologic Sales and Service, LLC | $73.97 | 2019-2023 | Aptima |
| Mayne Pharma Commercial LLC | $64.81 | 2024-2025 | |
| Dexcom, INC. | $54.51 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $46.28 | 2024-2025 | Nexplanon |
| Therapeuticsmd, INC. | $46.05 | 2021-2022 | |
| Evofem Biosciences, INC. | $44.27 | 2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $43.95 | 2019-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $41.18 | 2025 | |
| Millicent US INC | $39.56 | 2025 | Intrarosa, Femlyv |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $39.19 | 2019-2022 | |
| Renovia INC | $33.89 | 2021 | |
| Sumitomo Pharma America, INC. | $31.83 | 2023-2024 | Myfembree |
| Daiichi Sankyo INC. | $28.23 | 2024 | Injectafer |
| Amgen INC. | $27.92 | 2019-2020 | |
| Baxter Healthcare | $26.28 | 2019 | |
| Ethicon US, LLC | $26.24 | 2020 | |
| Davol INC. | $24.46 | 2023 | Arista Ah Flexitip |
| Abbott Laboratories | $14.20 | 2022 | |
| Avion Pharmaceuticals | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Drennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.